Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E.; Sengstock, G.J.; Riederer, P.; Olanow, C.W.; Dunn, A.J.; Arendash, G.W.

doi:10.1016/0006-8993(94)90833-8

Cited by 156Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismIron Metabolism and Disorders

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E., Sengstock, G.J., Riederer, P., Olanow, C.W., Dunn, A.J., Arendash, G.W.·1994·Brain Research

DOI 10.1016/0006-8993(94)90833-8

Open this paper in CoChat — free account

Abstract

Parkinson's-diseased (PD) brains have increased levels of iron in the zona compacta of the substantia nigra (SNc). To determine whether these elevated nigral iron levels may be caused secondarily by degeneration of nigrostriatal dopaminergic (NS-DA) neurons, the NS-DA pathway was unilaterally lesioned in rats through 6-hydroxydopamine (6-OHDA) infusion and nigral iron levels evaluated three weeks later. A significant increase was observed in both iron concentration (+35%) and iron content (+33) within the substantia nigra (SN) ipsilateral to comprehensive 6-OHDA lesions. Moreover, ferric iron staining was dramatically increased within the SNc following 6-OHDA lesions, primarily due to the appearance of iron-positive SNc neurons and infiltrating reactive glial cells. Iron staining in the SN zona reticularis was modestly increased after 6-OHDA lesions, but staining in the neostriatum and globus pallidus was unaffected. These results indicate that loss of NS-DA neurons is associated with increased iron levels in the SN. This suggests that increased nigral iron levels in PD may be secondary to some neurodegenerative process. Nonetheless, even a secondary increase in nigral iron levels may be of pathogenic importance in PD because of iron's ability to catalyze neurotoxic free radical formation and perpetuate neurodegeneration.

Integrity signals

Registry

Crossref · 10.1016/0006-8993(94)90833-8

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In the 6-hydroxydopamine model of Parkinson's disease, the degeneration of nigrostriatal dopaminergic neurons is associated with increased iron accumulation.
“Moreover, in the 6-hydroxydopamine model of Parkinson’s disease the degeneration of nigrostriatal dopaminergic neurons is associated with increased iron accumulation.155”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [155]

Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482 · see citing works
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · see citing works
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · see citing works
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427 · see citing works
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397 · see citing works
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · see citing works
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · see citing works
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149 · see citing works
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043 · see citing works
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain
Sofic, E., Riederer, P. F., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G. F., & Youdim, M. B. H. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244786 · Cited by 754 · see citing works
Parkinson's disease: A disorder due to nigral glutathione deficiency?
Perry, T. L., Godin, D. V., & Hansen, S. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90390-1 · Cited by 753 · see citing works
Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?
Gerlach, M., Ben‐Shachar, D., Riederer, P. F., & Youdim, M. B. H. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63030793.x · Cited by 704 · see citing works
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
Sofic, E., Lange, K. W., Jellinger, K. A., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 591 · see citing works
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
Jenner, P. G., Dexter, D. T., Sian, J., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 545 · see citing works
Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains
Sofic, E., Paulus, W., Jellinger, K. A., Riederer, P. F., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02017.x · Cited by 523 · see citing works
The regional distribution and cellular localization of iron in the rat brain
Hill, J. M., & Switzer, R. C. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90046-0 · Cited by 486 · see citing works
Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445 · see citing works
Self-citation
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study
Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91334-b · Cited by 427 · see citing works
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382 · see citing works
Planning and spatial working memory in Parkinson's disease.
Morris, R. G., Downes, J. J., Sahakian, B. J., Evenden, J. L., HEALD, A., & Robbins, T. W. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.757 · Cited by 359 · see citing works
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313 · see citing works
The possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301 · see citing works
The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons
Ben‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299 · see citing works
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01782.x · Cited by 292 · see citing works
Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease
Ben‐Shachar, D., Riederer, P. F., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06358.x · Cited by 287 · see citing works
Studies on Parkinson's Disease Including X-Ray Fluorescent Spectroscopy of Formalin Fixed Brain Tissue
Earle, K. M. (1968) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-196801000-00001 · Cited by 227 · see citing works
Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats
Ben‐Shachar, D., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb06432.x · Cited by 197 · see citing works
Brain neurotransmitter changes in Parkinson's disease
Hornykiewicz, O. (1981) · Movement Disorders · doi:10.1016/b978-0-407-02295-9.50009-6 · Cited by 160 · see citing works
Stress‐Related Changes in Cerebral Catecholamine and Indoleamine Metabolism: Lack of Effect of Adrenalectomy and Corticosterone
Dunn, A. J. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01053.x · Cited by 145 · see citing works
Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis
Temlett, J. A., Landsberg, J. P., Watt, F., & Orime, G. W. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.62010134.x · Cited by 137 · see citing works
Nonidentical distribution of transferrin and ferric iron in human brain
Dwork, A. J., Schon, E. A., & Herbert, J. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90242-4 · Cited by 130 · see citing works
6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
Monteiro, H. P., & Winterbourn, C. C. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90512-1 · Cited by 125 · see citing works
Iron in Brain Function and Dysfunction with Emphasis on Parkinson’s Disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (2008) · European Neurology · doi:10.1159/000116719 · Cited by 106 · see citing works
Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers
Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., & Arendash, G. W. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350109 · Cited by 105 · see citing works
An autoradiographic study of the uptake and distribution of iron by the brain of the young rat
Dwork, A. J., Lawler, G., ZYBERT, P. A., Durkin, M. M., Osman, M., Willson, N. J., & Barkai, A. I. (1990) · Brain Research · doi:10.1016/0006-8993(90)90950-g · Cited by 99 · see citing works
Iron induces degeneration of nigrostriatal neurons
Sengstock, G. J., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90118-h · Cited by 90 · see citing works
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.
Dexter, D. T., Sian, J., Jenner, P. G., & MARSDEN, C. D. (1993) · PubMed · Cited by 82 · see citing works
Modulation by neuromelanin of the availability and reactivity of metal ions
Swartz, H. M., Sarna, T., & Zecca, L. (1992) · Annals of Neurology · doi:10.1002/ana.410320712 · Cited by 73 · see citing works
Iron concentration reduced in ventral pallidum, globus pallidus, and substantia nigra by GABA-transaminase inhibitor, gamma-vinyl GABA
Hill, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)91348-4 · Cited by 71 · see citing works
The role of iron in the basal ganglion.
Youdim, M. B. H., Ben‐Shachar, D., Yehuda, S., & Riederer, P. F. (1990) · PubMed · Cited by 55 · see citing works
Toxin-Induced Models of Neurological Disorders
Barker, R. B. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.1.109-a · Cited by 52 · see citing works
MRI, brain iron and experimental Parkinson's disease
Hall, S., Rutledge, J. N., & Schallert, T. J. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90247-i · Cited by 49 · see citing works
Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment
Ben‐Shachar, D., Pinhassi, B., & Youdim, M. B. H. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90292-x · Cited by 16 · see citing works
Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.
Leenders, K. L., Antonini, A., Schwarzbach, R., Smith-Jones, P. M., Reist, H. W., Ben‐Shachar, D., Youdim, M. B. H., & Henn, V. S. (1994) · PubMed · Cited by 13 · see citing works
Intranigral Iron Infusion as a Model for Parkinson’s Disease
Arendash, G. W., Sengstock, G. J., Olanow, C. W., Barone, S., & Dunn, A. J. (1994) · Springer eBooks · doi:10.1007/978-1-4899-1447-7_7 · Cited by 6 · see citing works

Flagged first, then by citations

2 of the 47 references couldn’t be matched to a known paper.

Sorted by citations

The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819 · see citing works
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801 · see citing works
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,394 · see citing works
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Blum, D. L., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A., Sadoul, R., & Verna, J. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246 · see citing works
Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105343200 · Cited by 1,103 · see citing works
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · see citing works
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Duty, S., & Jenner, P. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 758 · see citing works
Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: A review of their intracellular targets
Ramassamy, C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.025 · Cited by 680 · see citing works
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J., & Uversky, V. N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 656 · see citing works
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases
Weinreb, O., Mandel, S. A., Amit, T., & Youdim, M. B. H. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.05.002 · Cited by 506 · see citing works
A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders
Uversky, V. N. (2003) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2003.10506918 · Cited by 502 · see citing works
Invited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499 · see citing works
Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
Gerlach, M., & Riederer, P. F. (1996) · Journal of Neural Transmission · doi:10.1007/bf01291788 · Cited by 496 · see citing works
The pathogenesis of cell death in Parkinson's disease
Jenner, P. G., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 449 · see citing works
Glutathione, iron and Parkinson’s disease
Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01174-7 · Cited by 394 · see citing works
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases
Mandel, S. A., Weinreb, O., Amit, T., & Youdim, M. B. H. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02291.x · Cited by 379 · see citing works
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S. A., Youdim, M. B. H., & Riederer, P. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 349 · see citing works
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
Götz, M. E., Double, K. L., Gerlach, M., Youdim, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 342 · see citing works
Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332 · see citing works
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303 · see citing works
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246 · see citing works
Neuroprotective Strategies in Parkinson???s Disease
Mandel, S. A., Grünblatt, E., Riederer, P. F., Gerlach, M., Levites, Y., & Youdim, M. B. H. (2003) · CNS Drugs · doi:10.2165/00023210-200317100-00004 · Cited by 238 · see citing works
Dopamine, 6-hydroxydopamine, iron, and dioxygen — their mutual interactions and possible implication in the development of Parkinson's disease
Linert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K. A., & Youdim, M. B. H. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(96)00020-8 · Cited by 238 · see citing works
Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28
YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233 · see citing works
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218 · see citing works
Extracellular Dopamine Potentiates Mn-Induced Oxidative Stress, Lifespan Reduction, and Dopaminergic Neurodegeneration in a BLI-3–Dependent Manner in Caenorhabditis elegans
Benedetto, A., Au, C., Ávila, D. S., Milatović, D., & Aschner, M. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001084 · Cited by 196 · see citing works
Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases.<i>In vivo</i>selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185 · see citing works
Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes
Wang, Y., Wu, S., Li, Q., Sun, H., & Wang, H. (2023) · Advanced Science · doi:10.1002/advs.202300325 · Cited by 161 · see citing works
New Insights into Toxicity and Drug Testing
Gowder, S. J. (2013) · InTech eBooks · doi:10.5772/55886 · Cited by 149 · see citing works
Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators
Zhu, W., Xie, W., Pan, T., Xu, P., Fridkin, M., Zheng, H., Jankovic, J. J., Youdim, M. B. H., & Le, W. (2007) · The FASEB Journal · doi:10.1096/fj.07-8386com · Cited by 137 · see citing works
The role of transition metals in the pathogenesis of Parkinson's disease.
Kienzl, E., Puchinger, L., Jellinger, K., Linert, W., Stachelberger, H., & Jameson, R. (1995) · Journal of Neurological Sciences · doi:10.1016/0022-510x(95)00210-s · Cited by 129 · see citing works
Dysregulation of Iron Homeostasis in the Central Nervous System and the Role of Ferroptosis in Neurodegenerative Disorders
David, S., Jhelum, P., Ryan, F., Jeong, S. Y., & Kroner, A. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0218 · Cited by 133 · see citing works
Manganese-Induced Dopaminergic Neurodegeneration: Insights into Mechanisms and Genetics Shared with Parkinson’s Disease
Benedetto, A., Au, C., & Aschner, M. (2009) · Chemical Reviews · doi:10.1021/cr800536y · Cited by 127 · see citing works
Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases
Breydo, L., & Uversky, V. N. (2011) · Metallomics · doi:10.1039/c1mt00106j · Cited by 126 · see citing works
Inflaming the Brain with Iron
Urrutia, P. J., Bórquez, D. A., & Núñez, M. (2021) · Antioxidants · doi:10.3390/antiox10010061 · Cited by 121 · see citing works
Quantitative elemental bio-imaging of Mn, Fe, Cu and Zn in 6-hydroxydopamine induced Parkinsonism mouse models
Hare, D. J., Reedy, B. J., Grimm, R., Wilkins, S., Volitakis, I., George, J. L., Cherny, R. A., Bush, A. I., Finkelstein, D. I., & Doble, P. (2008) · Metallomics · doi:10.1039/b816188g · Cited by 120 · see citing works
Iron, neuroinflammation, and Alzheimer's disease
Ong, W.-Y., & Farooqui, A. A. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8211 · Cited by 119 · see citing works
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease
Foley, P., & Riederer, P. F. (2000) · Journal of Neurology · doi:10.1007/pl00007766 · Cited by 119 · see citing works
Potential sources of increased iron in the substantia nigra of parkinsonian patients
Gerlach, M., Double, K. L., Youdim, M. B. H., & Riederer, P. F. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_21 · Cited by 109 · see citing works
Neonatal Iron Exposure Induces Neurobehavioural Dysfunctions in Adult Mice
Fredriksson, A., Schröder, N., Eriksson, P., Izquierdo, I., & Archer, T. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8711 · Cited by 108 · see citing works
Animal models of tremor
Wilms, H., Sievers, J., & Deuschl, G. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 171 · see citing works
Metalloproteomics and metal toxicology of α-synuclein
Santner, A. A., & Uversky, V. N. (2010) · Metallomics · doi:10.1039/b926659c · Cited by 104 · see citing works
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
Grünblatt, E., Mandel, S. A., & Youdim, M. B. H. (2000) · Journal of Neurology · doi:10.1007/pl00022909 · Cited by 105 · see citing works
Impaired iron homeostasis in Parkinson’s disease
Double, K. L., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_3 · Cited by 99 · see citing works
Dietary plant polyphenols as the potential drugs in neurodegenerative diseases: current evidence, advances, and opportunities
Yan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97 · see citing works
Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
Grünblatt, E., Mandel, S. A., Maor, G., & Youdim, M. B. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00227.x · Cited by 96 · see citing works
The Divalent Metal Transporter Homologues SMF-1/2 Mediate Dopamine Neuron Sensitivity in Caenorhabditis elegans Models of Manganism and Parkinson Disease
Settivari, R. S., LeVora, J., & Nass, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051409 · Cited by 95 · see citing works
p‐quinone mediates 6‐hydroxydopamine‐induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p‐quinone into melanin extracellularly
Izumi, Y., Sawada, H., Sakka, N., Yamamoto, N., Kume, T., Katsuki, H., Shimohama, S., & Akaike, A. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20382 · Cited by 95 · see citing works
Neuroprotective Strategies in Parkinson's Disease Using the Models of 6‐Hydroxydopamine and MPTPa
Grünblatt, E., Mandel, S. A., & Youdim, M. B. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06192.x · Cited by 91 · see citing works
Multifunctional drugs with different CNS targets for neuropsychiatric disorders
der Schyf, C. J. V., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04141.x · Cited by 88 · see citing works
Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period
Fredriksson, A., Schröder, N., Eriksson, P., Izquierdo, I., & Archer, T. (2000) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00160-1 · Cited by 86 · see citing works
The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators
Youdim, M. B. H., Grünblatt, E., & Mandel, S. A. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07977.x · Cited by 85 · see citing works
Short-Term Supplementation with Plant Extracts Rich in Flavonoids Protect Nigrostriatal Dopaminergic Neurons in a Rat Model of Parkinson's Disease
Datla, K. P., Zbarsky, V., Rai, D., Parkar, S., Osakabe, N., Aruoma, O. I., & Dexter, D. T. (2007) · Journal of the American College of Nutrition · doi:10.1080/07315724.2007.10719621 · Cited by 83 · see citing works
Die Parkinson-Krankheit
Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 83 · see citing works
Microglia activation is related to substantia nigra echogenicity
Berg, D., Godau, J., Riederer, P. F., Gerlach, M., & Arzberger, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0504-6 · Cited by 83 · see citing works
Elemental profile of cerebrospinal fluid in patients with Parkinson's disease
Alimonti, A., Bocca, B., Pino, A., Ruggieri, F., Forte, G., & Sancesario, G. (2007) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2007.05.001 · Cited by 80 · see citing works
6-Hydroxydopamine: a far from simple neurotoxin
Varešlija, D., Tipton, K. F., Davey, G. P., & McDonald, A. G. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-019-02133-6 · Cited by 77 · see citing works
Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9070-9 · Cited by 75 · see citing works
Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain
Hare, D. J., George, J. L., Grimm, R., Wilkins, S., Adlard, P. A., Cherny, R. A., Bush, A. I., Finkelstein, D. I., & Doble, P. (2010) · Metallomics · doi:10.1039/c0mt00039f · Cited by 75 · see citing works
Parkinson’s Disease: The Mitochondria-Iron Link
Muñoz, Y., Carrasco, C. M., Campos, J., Aguirre, P., & Núñez, M. T. (2016) · Parkinson s Disease · doi:10.1155/2016/7049108 · Cited by 73 · see citing works
Magnetic Resonance Imaging of Corticobasal Degeneration
Hauser, R. A., Murtagh, F. R., Akhter, K., Gold, M., & Olanow, C. W. (1996) · Journal of Neuroimaging · doi:10.1111/jon199664222 · Cited by 72 · see citing works
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
Riederer, P. F., Monoranu, C., Strobel, S., Iordache, T., & Sian‐Hülsmann, J. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02414-z · Cited by 69 · see citing works
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
Riederer, P. F., Nagatsu, T., Youdim, M. B. H., Wulf, M., Dijkstra, J. M., & Sian‐Hülsmann, J. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02630-9 · Cited by 68 · see citing works
Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity
Mohanakumar, K. P., Hanbauer, I., & Chiueh, C. C. (1998) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(98)00032-5 · Cited by 67 · see citing works
Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases
der Schyf, C. J. V., Gal, S., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.873 · Cited by 66 · see citing works
Combined Elemental and Biomolecular Mass Spectrometry Imaging for Probing the Inventory of Tissue at a Micrometer Scale
Matusch, A., Fenn, L. S., Depboylu, C., Klietz, M., Strohmer, S., MCLEAN, J. A. J., & Becker, J. S. (2012) · Analytical Chemistry · doi:10.1021/ac203112c · Cited by 66 · see citing works
Neuroinflammation in Parkinson’s Disease Animal Models: A Cell Stress Response or a Step in Neurodegeneration?
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_356 · Cited by 65 · see citing works
Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
Kienzl, E., Jellinger, K. A., Stachelberger, H., & Linert, W. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00458-0 · Cited by 62 · see citing works
Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease
Liddell, J. R., & White, A. R. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.016 · Cited by 62 · see citing works
Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys
He, Y., Thong, P. S. P., Lee, T. T., Leong, S. K., Mao, B. Y., Dong, F., & Watt, F. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00385-x · Cited by 62 · see citing works
Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study
He, Y., Thong, P. S. P., Lee, T., Leong, S. K., Shi, C., Wong, P. T. ‐., Yuan, S. Y., & Watt, F. (1996) · Brain Research · doi:10.1016/0006-8993(96)00313-7 · Cited by 61 · see citing works
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease
Gal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_68 · Cited by 58 · see citing works
Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo
Ferger, B., Spratt, C., Teismann, P., SEITZ, G., & Kuschinsky, K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00696-7 · Cited by 54 · see citing works
Biosynthesis, Structure, and Function of Neuromelanin and its Relation to Parkinson's Disease: A Critical Update
d’Ischia, M., & Prota, G. (1997) · Pigment Cell Research · doi:10.1111/j.1600-0749.1997.tb00694.x · Cited by 53 · see citing works
Pathogenesis and preclinical course of Parkinson’s disease
Foley, P., & Riederer, P. F. (1999) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6360-3_2 · Cited by 50 · see citing works
Dopamine neurotoxicity: age-dependent behavioral and histological effects
Cantuti‐Castelvetri, I., Shukitt‐Hale, B., & Joseph, J. A. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00186-0 · Cited by 45 · see citing works
Selegiline protects against recognition memory impairment induced by neonatal iron treatment
DELIMA, M., Laranja, D. C., Caldana, F., Grazziotin, M. M., GARCIA, V., Dal‐Pizzol, F., Bromberg, E., & Schröder, N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.07.017 · Cited by 45 · see citing works
Alpha-synuclein inhibits Snx3–retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson’s disease
Patel, D., Xu, C., Nagarajan, S., Liu, Z., Hemphill, W. O., Shi, R., Uversky, V. N., Caldwell, G. A., Caldwell, K. A., & Witt, S. N. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy059 · Cited by 44 · see citing works
Methamphetamine increases basal ganglia iron to levels observed in aging
Melega, W. P., Laćan, G., Harvey, D. C., & Way, B. M. (2007) · Neuroreport · doi:10.1097/wnr.0b013e3282f0d4f4 · Cited by 42 · see citing works
Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits
Fredriksson, A., Schröder, N., Eriksson, P. O., Izquierdo, I., & Archer, T. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(00)00028-6 · Cited by 42 · see citing works
Ferroptosis in Neurological Disease
David, S., Ryan, F., Jhelum, P., & Kroner, A. (2022) · The Neuroscientist · doi:10.1177/10738584221100183 · Cited by 42 · see citing works
Brain iron acquisition: An overview of homeostatic regulation and disease dysregulation
Baringer, S. L., Simpson, I. A., & Connor, J. R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15819 · Cited by 40 · see citing works
Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson's rats: Neuroprotection by serotonin, GABA and bone marrow cells supplementation
Kuruvilla, K. P., Nandhu, M. S., Paul, J., & Paulose, C. S. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.04.020 · Cited by 38 · see citing works
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease
Fine, J. M., Forsberg, A. C., Renner, D. B., Faltesek, K. A., Mohan, K., Wong, J. C., Arneson, L. C., Crow, J. M., Frey, W. H., & Hanson, L. R. (2014) · Brain Research · doi:10.1016/j.brainres.2014.05.048 · Cited by 39 · see citing works
Milestones in magnetic resonance imaging and transcranial sonography of movement disorders
Berg, D., Steinberger, J. D., Olanow, C. W., Naidich, T. P., & Yousry, T. A. (2011) · Movement Disorders · doi:10.1002/mds.23766 · Cited by 38 · see citing works
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
Mukaetova‐Ladinska, E. B., Monteith, R., & Perry, E. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/536538 · Cited by 37 · see citing works
The protective role of chelators and antioxidants on mancozeb-induced toxicity in rat hippocampal astrocytes
Tsang, M., & Trombetta, L. (2007) · Toxicology and Industrial Health · doi:10.1177/0748233708089039 · Cited by 37 · see citing works
Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells
Izumi, Y., Sawada, H., Yamamoto, N., Kume, T., Katsuki, H., Shimohama, S., & Akaike, A. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20595 · Cited by 37 · see citing works
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson’s disease?
Youdim, M. B. H. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_5 · Cited by 36 · see citing works
Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
Grünblatt, E., Mandel, S. A., Gassen, M., & Youdim, M. B. H. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6369-6_6 · Cited by 36 · see citing works
Sleep Disorders in Parkinson’s Disease: Clinical Features, Iron Metabolism and Related Mechanism
Yu, S., Sun, L. Z., Liu, Z., Huang, X., Zuo, L., Cao, C.-J., Zhang, W., & Wang, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082924 · Cited by 34 · see citing works
Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders
Jenner, P. G., & Olanow, C. W. (1996) · Elsevier eBooks · doi:10.1016/b978-012525445-8/50004-7 · Cited by 34 · see citing works
High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity
Burrows, K. B., & Meshul, C. K. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00506-5 · Cited by 33 · see citing works
Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review
Jesse, S., Steinacker, P., Lehnert, S., Gillardon, F., Hengerer, B., & Otto, M. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00064.x · Cited by 32 · see citing works
The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
Youdim, M. B. H., Grünblatt, E., & Mandel, S. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0499-1 · Cited by 31 · see citing works
Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning
He, Y., Lee, T., & Leong, S. K. (1999) · Free Radical Research · doi:10.1080/10715769900301611 · Cited by 30 · see citing works
M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models
Youdim, M. B. H. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70047-5 · Cited by 29 · see citing works
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons
Aguirre, P., Mena, N. P., Carrasco, C. M., Muñoz, Y., Pérez‐Henríquez, P., Morales, R. A., Cassels, B. K., Méndez‐Gálvez, C., García‐Beltrán, O., González-Billault, C. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144848 · Cited by 25 · see citing works
Complexities in the neurotoxic actions of 6-hydroxydopamine in relation to the cytoprotective properties of taurine
Hayes, J. P., Tipton, K. F., Bianchi, L., & Corte, L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00507-x · Cited by 25 · see citing works
Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration
Fredriksson, A., & Archer, T. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00035-9 · Cited by 25 · see citing works

Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers
Sengstock, G. J., Olanow, C. W., Menzies, R. A., Dunn, A. J., & Arendash, G. W. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350109 · Cited by 105 · see citing works
Iron induces degeneration of nigrostriatal neurons
Sengstock, G. J., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1992) · Brain Research Bulletin · doi:10.1016/0361-9230(92)90118-h · Cited by 90 · see citing works
Iron induces the degeneration of nigral dopaminergic neurons in rats
Zhoufan, W. (2002) · Zhonghua laonian yixue zazhi
Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study
He, Y., Thong, P. S. P., Lee, T., Leong, S. K., Shi, C., Wong, P. T. ‐., Yuan, S. Y., & Watt, F. (1996) · Brain Research · doi:10.1016/0006-8993(96)00313-7 · Cited by 61 · see citing works
Experimental Study of the Role of Iron in the Course of Dopaminergic Neurons
Fei, C. (2003) · Chinese Journal of Neuroimmunology and Neurology

Authors: Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W.
Affiliations: University of Würzburg (DE)
University of South Florida (US)
Louisiana State University (US)
Corresponding author: Arendash, G.W.
ORCID: Riederer, P.
Olanow, C.W.
Arendash, G.W.
Venue: Brain Research
Publisher: Elsevier BV
Published: 1994-10
Volume: 660
Issue: 1
Pages: 8-18
ISSN: 0006-8993 (ISSN-L)
DOI: 10.1016/0006-8993(94)90833-8
OpenAlex: W2049800884
Cited by: 156
References: 47
Citations by year: 2026: 1 · 2025: 1 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 7 · 2012: 4
FWCI: 3.39
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Brain Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords: Parkinson's disease, nigrostriatal dopaminergic neurons, substantia nigra, iron accumulation, 6-hydroxydopamine lesion, neurodegeneration, reactive glial cells
MeSH terms: Amphetamine, Animals, Behavior, Animal, Corpus Striatum, Histocytochemistry, Iron, Male, Medial Forebrain Bundle, Nerve Degeneration, Neurons, Stereotyped Behavior, Substantia Nigra, Oxidopamine, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks